Grazoprevir Hydrate

N/A

Report date: 2022/08/10 14:08:02
NME

Base Information

Drug NameGrazoprevir Hydrate
Drug Alias Namegrazoprevir戈雷瑞韦grazoprevirum格拉瑞韦格佐普韦 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsRenal InsufficiencyHepatitis C, ChronicHepatitis C +[4] 
Global Approved IndicationsHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2016/09/28
Country/TerritorySwitzerlandMainland ChinaJapan
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesMerck Sharp & Dohme Corp
China Registration ClassN/A

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMSD R&D（China）Co Ltd
Inactive CompaniesUniversity of ZurichMerck Sharp & Dohme LLC
Active IndicationsHepatitis C
Inactive IndicationsRenal InsufficiencyHepatitis C, ChronicHIV Infections

Other Information

ATC CodeJ05AP11
Related LinksWikipediaDrugBankKEGG